Celltrion says its COVID-19 antibody shows ‘strong neutralising activity’ against Delta variant
A therapeutic dose of regdanvimab also reduced the viral load of the SARS-CoV-2 virus and inflammation in the lungs
Read More
Tag: Celltrion
MHRA OKs Celltrion’s Phase I trial of COVID drug
The trial will enrol patients with mild symptoms of SARS-CoV-2 infection to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of CT-P59
Read More
Celltrion’s infliximab biosimilar to be tested for COVID-19
Infliximab has been chosen because of its effective role in treating autoimmune and inflammatory conditions and established safety profile
Read More
Celltrion calls for wider use of biologics in RA
Celltrion Healthcare is calling on the NHS to consider lowering the threshold for starting biologics in patients with rheumatoid arthritis (RA), and to put in place measures to boost patient access to such treatment.
Read More
Herceptin biosimilar Herzuma launched in Europe
Mundipharma announced that its network of companies has kicked off the rollout of Celltrion’s Herceptin biosimilar Herzuma in Europe.
Read More
US delay for Celltrion’s Rituxan, Herceptin biosimilars
The US Food and Drug Administration has rejected Celltrion’s submissions for biosimilars to Roche drugs Rituxan and Herceptin.
Read More
Napp secures distribution rights to Celltrion’s Herzuma
Napp Pharmaceuticals has secured itself exclusive UK distribution rights to Celltrion Healthcare’s Herceptin biosimilar Herzuma.
Read More
Green light for Celltrion’s Herceptin biosimilar
The European Commission has approved Celltrion Healthcare’s Herzuma, a biosimilar of Roche/Genentech’s blockbuster Herceptin.
Read More
Seven therapies backed for EU approval
Seven therapies have been put forward for approval in the European Union, bringing closer new options for a range of conditions including Crohn’s disease, diabetes and cancer.
Read More
Pfizer, Celltrion say data backs switch to Remicade biosimilar
Pfizer and Celltrion Healthcare have unveiled new data showing that switching patients with Crohn’s disease from Remicade to biosimilar Inflectra showed comparable efficacy, safety and tolerability over a 24-week period.
Read More
Biosimilar Inflectra matches Remicade efficacy in trial
Pfizer and Celltrion have unveiled Phase III study data comparable safety and efficacy between biosmilar Inflectra and reference drug Remicade in patients with moderate-to-severe Crohn’s disease (CD).
Read More
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
- NIHR and TJBCM announce new funding initiative for novel brain tumour research
- UKHSA and ICL confirm variant which plays key role in global surge of Strep A infections
